Shareholder
Information

Shareholder Information

Sequent Scientific Limited is India’s leading animal health company.

Bank Loan Facilities - Long Term

YearRating AgenciesRating Assigned
2023-24Ind-RaIND A with negative outlook
2024-25Ind-RaIND A with Positive outlook

Bank Loan Facilities - Short Term

YearRating AgenciesRating Assigned
2023-24Ind-RaA1
2024-25Ind-RaA1

Financial Year ending March 31, 2024 -FY 2023-24

Financial Year ending March 31, 2023 – FY 2022-23

Financial Year ending March 31, 2022 – FY 2021-22

Financial Year ending March 31, 2018 – Interim Dividend FY 2017-18

Unpaid Dividend_2017-18- List of shareholders whose Interim Dividend is unpaid and unclaimed for FY 2017-18 and is liable to be transferred to IEPF if not claimed.

Financial year ending March 31, 2017 – List of shareholders whose Equity Shares are liable to be transferred to IEPF for Interim dividend declared in FY 2017-18.

Financial Year ending March 31, 2018 – FY 2010-11

Financial Year ending March 31, 2016 – List of Shareholders whose shares are to be transferred to IEFP Authority

Financial Year ending March 31, 2016 – FY 2009-10

Financial Year ending March 31, 2015 – FY 2010-11

Financial Year ending March 31, 2015 – FY 2009-10

Financial Year ending March 31, 2015 – FY 2008-09

Financial Year ending March 31, 2014 – FY 2010-11

Financial Year ending March 31, 2014 – FY 2009-10

Financial Year ending March 31, 2014 – FY 2008-09

Financial Year ending March 31, 2014 – FY 2007-08

Financial Year ending March 31, 2013 – FY 2010-11

Financial Year ending March 31, 2013 – FY 2009-10

Financial Year ending March 31, 2013 – FY 2008-09

Financial Year ending March 31, 2013 – FY 2007-08

Financial Year ending March 31, 2013 – FY 2006-07

Financial Year ending March 31, 2012 – FY 2010-11

Financial Year ending March 31, 2012 – FY 2009-10

Financial Year ending March 31, 2012 – FY 2008-09

Financial Year ending March 31, 2012 – FY 2007-08

Financial Year ending March 31, 2012 – FY 2006-07

Financial Year ending March 31, 2011 – FY 2010-11

Financial Year ending March 31, 2011 – FY 2009-10

Financial Year ending March 31, 2011 – FY 2008-09

Financial Year ending March 31, 2011 – FY 2007-08

Financial Year ending March 31, 2011 – FY 2006-07

Report of Scrutinizer- Appointment of Ms. Revati Parag Kasture

Newspaper Publication for Q3 Financial results

  • Q3

Outcome of Board Meeting February 11, 2025

  • Q3
  • 2024-2025

Investor meet Intimation February 13, 2025

Board Meeting Intimation – February 11, 2025

Notice of postal ballot- Appointment of Independent Director

Trading window closure

Update on change in Directorate and Key Managerial Personnel

Newspaper publication for shifting of Registered office

Report of Scrutinizer-Shifting of Registered office

Acquisition of (i) N-VET AB, Sweden (ii) Alivira Italia SRL, Italy

Investor Presentation Q2 FY25

Outcome of Board Meeting November 13, 2024

Intimation of Board Meeting – November 13, 2024

Investor Meet Intimation -November 14, 2024

Newspaper Advertisement – Notice of postal ballot for shifting of RO

Notice of postal ballot – SSL Change of RO – October 29, 2024

Press Release- August 19, 2024

Newspaper Advertisement – Extract of unaudited Financial results – June 30, 2024

ESOP Grant under SeQuent Scientific Employee Stock Option Plan 2020 dated September 06, 2024

Proceedings of Thirty NINTH Annual General Meeting of the Company

Closure of trading window

Investor meet Intimation – October 09, 2024

Shifting of Registered Office and amendment in MOA

Intimation of Board Meeting – August 14, 2024

Investor Meet Intimation – August 14, 2024

Sequent Intimation Schedule of Analyst or Institutional Investors Meeting

Outcome of Postal Ballot – Results and Scrutinizer Report

Sequent Intimation Schedule of Analyst or Institutional Investors Meeting

Intimation for Closure of Trading Window – July 01, 2024

Newspaper Advertisement – Notice of Postal Ballot

Notice of postal Ballot dated 13-06-2024

Disclosure of Related Party Transactions for the half year ended September 30,2023

Outcome of a Board Meeting May 15, 2024

Investor Meet Intimation – May 16, 2024

Intimation of Board Meeting – May 15, 2024

Clarification w.r.t Outcome of Board meeting April 16,2024

Outcome of a Board Meeting February 13, 2024

Outcome of a Board Meeting February 05, 2024

Outcome of a Board Meeting November 06, 2023

Outcome of a Board Meeting September 14, 2023

Outcome of a Board Meeting August 10, 2023

Newspaper Publication of Financial Results for Q3 FY 2023-24

Intimation of Board Meeting Feb 13, 2024

Intimation of Board Meeting Nov 06, 2023

Intimation of Board Meeting Aug 10, 2023

Resignation of Joint Managing Director

Outcome of Postal Ballot – Results and Scrutinizer Report

Newspaper Advertisement – Notice of Postal Ballot

Notice of Postal Ballot

Amalgamation of Vila_Vina with Comercial Vila Vetrinaria

Appointment of Chief Financial Officer of the Company

Disclosure for USFDA observation

Discontinuation of Tarapur Operations

Resignation of Chief Financial Officer

Revision in Credit Rating

Sale of Land

Secretarial Compliance Report FY 2022-23

SE Resignation of CS

Earning Call Transcript

SeQuent Q1FY24 Con call Invite

AGM Notice – August 30, 2023

Disclosure under Regulation 30 -Earning Call Transcript

Newspaper Publication of Financial Results for Q4 FY 2022-23

Investor Meet Outcome – May 23, 2023

Investor Meet Intimation– May 24, 2023

Outcome of Board Meeting – May 23, 2023

Intimation of Board Meeting – May 23, 2023

Intimation for Closure of Trading Window – April 01, 2023

Disclosure under Regulation 30 -Earning Call Transcript

Newspaper Publication of Financial Results for Q3 FY 2022-23

Investor Meet Outcome – February 15, 2023

Outcome of Board Meeting – February 14, 2023

Investor Meet Intimation – February 15, 2023.

Intimation of Board Meeting – February 14, 2023.

Outcome of Postal Ballot – Results and Scrutinizer Report.

Announcement under Regulation 30 – Resignation of Director.

Newspaper Advertisement – Completion of dispatch of Postal Ballot Notice

Disclosure of Related Party Transactions for the half year ended September 30, 2022.

Notice of Postal Ballot

Outcome of Board Meeting – November 07, 2022

Disclosures under Regulation 30.

Investor Meet Intimation – November 08, 2022.

Intimation of Board Meeting – November 07, 2022.

AGM Proceedings – FY 2022.

Newspaper Advertisement-Post Dispatch of Notice of AGM

Newspaper Advertisement – 37th AGM to be held through VC / OAV

Newspaper Publication of Financial Results for Q1 FY 2022-23.

Re-constitution of Materiality Committee.

Outcome of Board Meeting held on August 08, 2022

Grant of Options under SeQuent ESOP 2020

Appointment of Chief Financial Officer of the Company

Disclosure of Related Party Transactions for the half year ended March 31, 2022

Secretarial Compliance Report FY 2021-22

Newspaper Publication of Financial Results for Q4 FY 2021-22

Constitution of “Materiality Committee”

Outcome of Board Meeting held on May 25, 2022

Investor Meet Intimation – May 26, 2022

Intimation of Board Meeting – May 25, 2022

Fire Incident at wholly owned subsidiary’s Unit

Allotment of Equity Shares under SeQuent ESOP 2020

Resignation of Chief Financial Officer

Grant of Options under SeQuent ESOP 2020

Outcome of Board Meeting held on February 11, 2022

Change in Managing Director and Chief Executive Officer of the Company

Consolidation of residual stake in Evance Group, Brazil

Acquisition of Nourrie

Intimation of Strike off Elysian Life Science Private Limited, a wholly owned subsidiary of the Company

Investor Meet Intimation – November 18 and 19, 2021

Outcome of Board Meeting held on November 01, 2021

Investor Meet Intimation – November 02, 2021

Intimation of Board Meeting – November 01, 2021

Intimation for Closure of Trading Window – October 01, 2021

Newspaper Advertisement – Extract of unaudited Financial results – June 30, 2021

Intimation of Board Meeting – June 30, 2021

Proceedings of Thirty Sixth Annual General Meeting of the Company

Post Newspaper AGM Intimation

Newspaper Advertisement – 36th AGM to be held through VC / OAV

Outcome of Board Meeting held on August 10, 2021

Investor Meet Intimation – August 11, 2021

Intimation of Board Meeting – August 10, 2021

Newspaper Advertisement – Extract of Audited Financial results – March 31, 2021

SeQuent announced EUGMP approval for its tablets dosage form in Turkey

Intimation for Closure of Trading Window – July 01, 2021

Outcome of Board Meeting held on June 30, 2021

Intimation for Closure of Trading Window – April 01, 2021

Related Party Transactions for the half year ended March 31, 2021

Related Party Transactions for the half year ended September 30, 2020

Newspaper Advertisement – Notice of Postal Ballot

Newspaper Advertisement – Extract of Unaudited Financial results – December 31, 2020

Press Release-January 28, 2021

Newspaper Advertisement – January 28, 2021

Investor Meet Intimation – February 4, 2021

Intimation of Board Meeting – February 3, 2021

Intimation for Closure of Trading Window – January 1, 2021

Schedule of meeting with investors/analysts – December 22, 2020

Outcome of Board Meeting held on December 14, 2020

Change in Director – Appointment of Dr. Fabian Kausche

Press Release – SeQuent announced launch of Citramox® LA in EU

Press Release – SeQuent announced launch of inhouse developed Halofusol® in EU

Related Party Transactions for the half year ended September 30, 2020

Newspaper Advertisement – Extract of Unaudited Financial results – September 30, 2020

Change in Directorate

Intimation pursuant to Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Intimation of Analysts/ Investors Conference call (Reschedule)

Update on Consolidation of Shareholding in Fendigo BV, Netherlands to make Fendigo BV a Wholly Owned Subsidiary of the Company

Investor Meet Intimation – November 6, 2020

Intimation of Board Meeting – November 6, 2020

Revision in Credit Rating

Completion of Sale of Investments held in Strides Pharma Science Limited

Request for reclassification of shareholding from ‘Promoter and Promoter Group’ to ‘Public’ Category’

Consolidation of shareholding in Provet Veteriner Urunleri San. Ve Tic. A. S., Turkey

Post Offer Advertisement

Pre-Offer Advertisement

Proceedings of Thirty Fifth Annual General Meeting of the Company

Board reconstitution

Press Release on Board reconstitution

Letter of Offer

Outcome of Board Meeting held on August 17, 2020

Change in Directorship

Withdrawal of Resolution No. 2 of the Notice dated July 30, 2020 convening the Thirty Fifth Annual General Meeting of the Company

Detailed Public Statement – Second Corrigendum

Recommendations of the Committee of Independent Directors (IDC) on the Open Offer

Outcome of Board Meeting held on August 12, 2020 and Press Release

Detailed Public Statement – Corrigendum

Newspaper Advertisement – Post dispatch of Notice of 35th AGM to be held through VC / OAVM

Newspaper Advertisement – Extract of Unaudited Financial results – June 30, 2020

Change in Directorate – Expiry of term of Mr. Narendra Mairpady, Independent Director

Newspaper Advertisement – 35th AGM to be held through VC / OAVM

Investor Meet Intimation – July 31, 2020

Intimation of Board Meeting – July 30, 2020

Intimation for Closure of Trading Window – July 1, 2020

Related Party Transactions for the year ended March 31, 2020

Draft Letter of Offer

Detailed Public Statement

Rescheduled Investor Meet Intimation – May 12, 2020

Intimation of Board Meeting – May 12, 2020

Investor Meet Intimation – May 12, 2020

Press Release – The Carlyle Group Enters into Binding Agreements to Acquire a Majority Stake in SeQuent

Intimation of Open Offer

Outcome of Board Meeting held on May 8, 2020

Press Release – Sequent Scientific provides Covid-19 Update

Intimation for Closure of Trading Window – April 1, 2020

Press Release – Sequent Scientific announces WHO-Geneva approval for its Vizag facility

Press Release – Sequent Scientific announces addition of new state-of-art Animal Health R&D Centre at Mumbai

Extract of Unaudited Financial Results in newspaper – December 31, 2019

Investor Meet Intimation – January 28, 2020

Intimation of Board Meeting – January 28, 2020

Intimation for Closure of Trading Window – January 1, 2020

Outcome of Board Meeting – November 13, 2019

Board Meeting – November 13, 2019

Disclosure of reasons for encumbrance by Promoters under regulation 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011

Outcome of Board Meeting – July 31, 2019

Intimation of Board Meeting – July 31, 2019

Investor Meet – July 31, 2019

Withdrawal of Credit Rating

Submission of half yearly disclosure on Related Party Transactions

Published Financials – May 14, 2019

Intimation of Board Meeeting – May 14, 2019

Investor Meet – May 14, 2019

Intimation of Credit Rating

Allotment of Shares

Change in RTA

Published Financials February 2, 2019

Intimation of Board Meeting – February 01, 2019

Investor Meet – February 01, 2019

SRL receives EIR from USFDA

Analyst Meet

Investor Meet – November 02, 2018

Intimation of Board Meeting – November 02, 2018

AGM Proceedings

Published Financials

Investor Meet – August 10, 2018

Intimation of Board Meeting – August 09, 2018

Investor Meet – May 25, 2018

Intimation of Board Meeting – May 24, 2018

Outcome of Board Meeting – May 24, 2018

Outcome of Board Meeting – February 9, 2018

Sequent Board Meeting Intimation – February 9, 2018

Investors complaint Statement – 2017 -18 Quarter ended 3

Investors complaint Statement – 2017 -18 Quarter ended 2

Outcome of Tribunal Convened Meeting December 26, 2017

Outcome of Board Meeting November 9, 2017

Sequent Board Meeting Intiamtion – November 09, 2017

Sequent Board Meeting Intiamtion – August 03, 2017

Sequent Board Meeting Intiamtion – May 23, 2017

Sequent Board Meeting Intiamtion – Feb 10, 2017

Outcome of Board Meeting August 3, 2017

Outcome of Board Meeting May 23, 2017

Outcome of Postal Ballot – Results

Outcome of Board Meeting March 20, 2017

Outcome of Board Meeting February 10, 2017

Sequent Outcome of Meeting November 10, 2016

Sequent Board Meeting Intimation November 10, 2016

Sequent Proceedings of AGM September 23, 2016

Sequent Outcome of Meeting September 23, 2016

Sequent AGM Advertisement September 1, 2016

Intimation to SE AGM September 23, 2016

Sequent Intimation to SE Book Closure

Sequent Form C Reg 7(2) SEBI (Prohibition of Insider Trading) Regulations, 2015 August 9, 2016

Sequent Form C Reg 7(2) SEBI (Prohibition of Insider Trading) Regulations 2015 May 17, 2016

Sequent Board Meeting Intimation August 12 2016

Submission of Consolidated Financials 2016-17

Update on Acquisition of Karizoo Group Spain

Sequent Intimation Alivira to acquire majority stake in Karizoo Group Spain

Grant of Employee Stock Options under SSL ESOP Scheme – 2010 of the Company

Sequent Outcome of Board Meeting May 14, 2016

Sequent Board Meeting Intimation May 14, 2016

Alivira to acquire controlling interest in Interchange Brazil

Sequent Intimation Schedule of Analyst or Institutional Investors Meeting

Sequent Update on Increase in Foreign Investment Limit March 14, 2016

Sequent Intimation for Record Date Equity Shares

Sequent Intimation for Appointment of Director

Sequent Intimation for Cessation from Directorship

Sequent Intimation to BSE Update on Vizag Plant February 5, 2016

Board Meeting Intimation February 11, 2016

Sequent Intimation Update on Indo Phyto Chemicals (“IPC”)

Sequent Intimation to BSE Update on Vizag Plant January 29, 2016

Sequent Scientific to acquire controlling stake in Indo Phyto Chemicals Forays into steroids and hormones for Female Healthcare

Grant of Employee Stock Options under SSL ESOP Scheme-2010

Intimation Dispatch of Postal Ballot Notice

Authorised KMPs to determine materiality of events/information

Completion of acquisition of Topkim, Turkey
SeQuent Scientific Limited (BSE: 512529, NSE: SEQUENT), headquartered in India, operates in Animal Health market with a global footprint. SeQuent has seven manufacturing facilities based in India, Spain, Brazil and Turkey with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc. SeQuent currently produces APIs and Animal health formulations in over 100 countries and has more than 1,500 employees.

Investor Relation

Company

Privacy & Policy

© 2024 Sequent. All rights reserved

Crafted by : Version-Next